Supportive Care in Cancer

, Volume 18, Issue 12, pp 1531–1538 | Cite as

Pharmaceutical interventions facilitate premedication and prevent opioid-induced constipation and emesis in cancer patients

  • Masashi Ishihara
  • Hirotoshi Iihara
  • Shinji Okayasu
  • Koji Yasuda
  • Katsuhiko Matsuura
  • Masumi Suzui
  • Yoshinori Itoh
Original Article



Opioid analgesics possess a number of side effects, among which constipation and nausea/vomiting occur most frequently. Although pretreatment with laxatives and antiemetics for the prophylaxis of opioid-induced constipation and nausea/vomiting, respectively, is recommended, such side effects are still a matter of concern in clinical setting.


We first surveyed the prevalence of premedication in 83 cancer patients who took opioid analgesics and the incidence of such side effects. Subsequently, intervention was carried out to promote premedication, and the effectiveness of the intervention was evaluated in 107 patients.


Prophylactic treatment with laxatives and antiemetics were conducted in 57% and 52%, respectively. The most frequently prescribed laxatives and antiemetics were magnesium oxide in combination with pantethine, a mild stimulant laxative, and prochlorperazine, respectively. The lack of premedication increased the risk of constipation (odds ratio, 5.25; 95% confidence intervals, 1.93–14.31; p = 0.001) and vomiting (4.67, 1.04–21.04; p = 0.045). Intervention such as provision of drug information to physicians, verification of prescription orders, and instructions to patients increased the rates of prophylactic medications to 93% (p < 0.001) for laxatives and 81% (p < 0.001) for antiemetics. The incidence of side effects was lowered from 36% to 9% (p < 0.001) for constipation, from 28% to 17% for nausea (p = 0.077), and from 16% to 4% for vomiting (p = 0.0085).


Intervention to promote prophylactic medication was highly effective in reducing the risk of opioid-induced constipation and nausea/vomiting.


Opioid analgesic Constipation Nausea/vomiting Prophylaxis Laxatives Antiemetics 


  1. 1.
    Koeller JM (1990) Understanding cancer pain. Am J Hosp Pharm 47(8 Suppl):S3–S6PubMedGoogle Scholar
  2. 2.
    Cohen MZ, Easley MK, Ellis C, Hughes B, Ownby K, Rashad BG, Rude M, Taft E, Westbrooks JB (2003) JCAHO. Cancer pain management and the JCAHO's pain standards: an institutional challenge. J Pain Symptom Manage 25:519–527CrossRefPubMedGoogle Scholar
  3. 3.
    Svendsen KB, Andersen S, Arnason S, Arnér S, Breivik H, Heiskanen T, Kalso E, Kongsgaard UE, Sjogren P, Strang P, Bach FW, Jensen TS (2005) Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain 9:195–206CrossRefPubMedGoogle Scholar
  4. 4.
    Schug SA, Zech D, Grond S, Jung H, Meuser T, Stobbe B (1992) A long-term survey of morphine in cancer pain patients. J Pain Symptom Manage 7:259–266CrossRefPubMedGoogle Scholar
  5. 5.
    Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H, Mercadante S, Pasternak G, Ventafridda V, Expert Working Group of the European Association of Palliative Care Network (2001) Strategies to manage the adverse effects of oral morphine: An evidence-based report. J Clin Oncol 19:2542–2554PubMedGoogle Scholar
  6. 6.
    McNicol E, Horowicz-Mehler N, Fisk RA, Bennett K, Gialeli-Goudas M, Chew PW, Lau J, Carr D (2003) American Pain Society. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain 4:231–256CrossRefPubMedGoogle Scholar
  7. 7.
    Fiocchi R, Bianchi G, Petrillo P, Tavani A, Manara L (1982) Morphine inhibits gastrointestinal transit in the rat primarily by impairing propulsive activity of the small intestine. Life Sci 31:2221–2223CrossRefPubMedGoogle Scholar
  8. 8.
    Foss JF, Bass AS, Goldberg LI (1993) Dose-related antagonism of the emetic effect of morphine by methylnaltrexone in dogs. J Clin Pharmacol 33:747–751PubMedGoogle Scholar
  9. 9.
    Davis MP, Walsh D (2000) Treatment of nausea and vomiting in advanced cancer. Support Care Cancer 8:444–452CrossRefPubMedGoogle Scholar
  10. 10.
    Shahbazian A, Heinemann A, Schmidhammer H, Beubler E, Holzer-Petsche U, Holzer P (2002) Involvement of mu- and kappa-, but not delta-, opioid receptors in the peristaltic motor depression caused by endogenous and exogenous opioids in the guinea-pig intestine. Br J Pharmacol 135:741–750CrossRefPubMedGoogle Scholar
  11. 11.
    Bhargava KP, Dixit KS, Gupta YK (1981) Enkephalin receptors in the emetic chemoreceptor trigger zone of the dog. Br J Pharmacol 72:471–475PubMedGoogle Scholar
  12. 12.
    Murphy DB, Sutton JA, Prescott LF, Murphy MB (1997) Opioid-induced delay in gastric emptying: a peripheral mechanism in humans. Anesthesiology 87:765–770CrossRefPubMedGoogle Scholar
  13. 13.
    Estfan B, Yavuzsen T, Davis M (2005) Development of opioid-induced delirium while on olanzapine: a two-case report. J Pain Symptom Manage 29:330–332CrossRefPubMedGoogle Scholar
  14. 14.
    Raffaeli W, Marconi G, Fanelli G, Taddei S, Borghi GB, Casati A (2006) Opioid-related side-effects after intrathecal morphine: a prospective, randomized, double-blind dose–response study. Eur J Anaesthesiol 23:605–610CrossRefPubMedGoogle Scholar
  15. 15.
    Gaudreau JD, Gagnon P, Roy MA, Harel F, Tremblay A (2007) Opioid medications and longitudinal risk of delirium in hospitalized cancer patients. Cancer 109:2365–2373CrossRefPubMedGoogle Scholar
  16. 16.
    Skaer TL (2004) Practice guidelines for transdermal opioids in malignant pain. Drugs 64:2629–2638CrossRefPubMedGoogle Scholar
  17. 17.
    Gordon DB, Dahl JL, Miaskowski C, McCarberg B, Todd KH, Paice JA, Lipman AG, Bookbinder M, Sanders SH, Turk DC, Carr DB (2005) American pain society recommendations for improving the quality of acute and cancer pain management: American Pain Society Quality of Care Task Force. Arch Intern Med 165:1574–1580CrossRefPubMedGoogle Scholar
  18. 18.
    National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology v.1. (2009) Adult cancer pain.
  19. 19.
    Williams PI, Smith M (1999) An assessment of prochlorperazine buccal for the prevention of nausea and vomiting during intravenous patient-controlled analgesia with morphine following abdominal hysterectomy. Eur J Anaesthesiol 16:638–645PubMedGoogle Scholar
  20. 20.
    Lloyd RS, Costello F, Eves MJ, James IG, Miller AJ (1992) The efficacy and tolerability of controlled-release dihydrocodeine tablets and combination dextropropoxyphene/paracetamol tablets in patients with severe osteoarthritis of the hips. Curr Med Res Opin 13:37–48PubMedGoogle Scholar
  21. 21.
    Klaschik E, Nauck F, Ostgathe C (2003) Constipation—modern laxative therapy. Support Care Cancer 11:679–685CrossRefPubMedGoogle Scholar
  22. 22.
    Meed SD, Kleinman PM, Kantor TG, Blum RH, Savarese JJ (1987) Management of cancer pain with oral controlled-release morphine sulfate. J Clin Pharmacol 27:155–161PubMedGoogle Scholar
  23. 23.
    Arce DA, Ermocilla CA, Costa H (2002) Evaluation of constipation. Am Fam Physician 65:2283–2290PubMedGoogle Scholar
  24. 24.
    Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176–181CrossRefPubMedGoogle Scholar
  25. 25.
    Hashizume T, Kasahara A, Oshima Y (1972) Biological studies of pantethine. 10. Effects of anesthetics on gastrointestinal-motility promoting effect of pantethine. Nippon Yakurigaku Zasshi 68:255–264PubMedGoogle Scholar
  26. 26.
    Kajiyama G, Kawamoto T, Fukuhara C, Horiuchi I, Nakagawa M, Miyoshi A (1981) The effect of pantethine, a precursor of coenzyme A, on bile acids and lipids in rats fed with a cholesterol diet. Hiroshima J Med Sci 30:215–220PubMedGoogle Scholar
  27. 27.
    Carrara P, Matturri L, Galbussera M et al (1984) Pantethine reduces plasma cholesterol and the severity of arterial lesions in experimental hypercholesterolemic rabbits. Atherosclerosis 53:255–264CrossRefPubMedGoogle Scholar
  28. 28.
    Cighetti G, Del Puppo M, Paroni R, Fiorica E, Galli Kienle M (1987) Pantethine inhibits cholesterol and fatty acid syntheses and stimulates carbon dioxide formation in isolated rat hepatocytes. J Lipid Res 28:152–161PubMedGoogle Scholar
  29. 29.
    Cighetti G, Del Puppo M, Paroni R, Galli Kienle M (1988) Modulation of HMG-CoA reductase activity by pantetheine/pantethine. Biochim Biophys Acta 963:389–393PubMedGoogle Scholar
  30. 30.
    Ventafridda V, Saita L, Ripamonti C, De Conno F (1985) WHO guidelines for the use of analgesics in cancer pain. Int J Tissue React 7:93–96PubMedGoogle Scholar
  31. 31.
    Stjernswärd J (1986) Cancer pain relief—an urgent public health problem. J Palliat Care 1:29–30PubMedGoogle Scholar
  32. 32.
    Hiraga K, Mizuguchi T, Takeda F (1991) The incidence of cancer pain and improvement of pain management in Japan. Postgrad Med J 67(Suppl 2):S14–S25PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Masashi Ishihara
    • 1
  • Hirotoshi Iihara
    • 1
  • Shinji Okayasu
    • 1
  • Koji Yasuda
    • 1
  • Katsuhiko Matsuura
    • 1
  • Masumi Suzui
    • 2
  • Yoshinori Itoh
    • 1
  1. 1.Department of PharmacyGifu University HospitalGifuJapan
  2. 2.Department of Medical Therapeutics and Molecular TherapeuticsGifu Pharmaceutical UniversityGifuJapan

Personalised recommendations